Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Receives $215.38 Consensus Target Price from Brokerages

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) has received an average recommendation of “Moderate Buy” from the sixteen analysts that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $215.3846.

A number of equities research analysts have commented on the stock. Weiss Ratings restated a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a research note on Friday, March 27th. Piper Sandler raised their price objective on shares of Jazz Pharmaceuticals from $219.00 to $232.00 and gave the company an “overweight” rating in a research report on Thursday, March 19th. Wells Fargo & Company lifted their target price on shares of Jazz Pharmaceuticals from $235.00 to $250.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. TD Cowen reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals in a report on Thursday, January 29th. Finally, Bank of America increased their price target on Jazz Pharmaceuticals from $263.00 to $275.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th.

Insiders Place Their Bets

In related news, CAO Patricia Carr sold 1,287 shares of the business’s stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $182.94, for a total value of $235,443.78. Following the transaction, the chief accounting officer directly owned 6,512 shares of the company’s stock, valued at approximately $1,191,305.28. The trade was a 16.50% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Mary Elizabeth Henderson sold 5,343 shares of the company’s stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $194.49, for a total value of $1,039,160.07. Following the completion of the transaction, the senior vice president owned 28,728 shares of the company’s stock, valued at $5,587,308.72. The trade was a 15.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 68,015 shares of company stock worth $13,037,486. 4.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. Hsbc Holdings PLC bought a new stake in Jazz Pharmaceuticals in the 4th quarter valued at $858,000. Corient Private Wealth LLC boosted its holdings in shares of Jazz Pharmaceuticals by 91.1% during the 4th quarter. Corient Private Wealth LLC now owns 10,200 shares of the specialty pharmaceutical company’s stock valued at $1,734,000 after purchasing an additional 4,863 shares during the last quarter. DGS Capital Management LLC bought a new position in shares of Jazz Pharmaceuticals during the 4th quarter valued at about $260,000. Pacer Advisors Inc. grew its position in shares of Jazz Pharmaceuticals by 19.8% during the fourth quarter. Pacer Advisors Inc. now owns 647,084 shares of the specialty pharmaceutical company’s stock valued at $110,004,000 after purchasing an additional 107,144 shares in the last quarter. Finally, Kera Capital Partners Inc. purchased a new position in shares of Jazz Pharmaceuticals during the fourth quarter valued at about $336,000. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

NASDAQ:JAZZ opened at $186.95 on Friday. The stock has a 50-day simple moving average of $177.03 and a two-hundred day simple moving average of $161.48. Jazz Pharmaceuticals has a 52-week low of $95.49 and a 52-week high of $198.00. The company has a debt-to-equity ratio of 1.00, a quick ratio of 1.67 and a current ratio of 1.86. The firm has a market capitalization of $11.51 billion, a PE ratio of -31.31, a P/E/G ratio of 0.34 and a beta of 0.23.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Wednesday, February 25th. The specialty pharmaceutical company reported $6.64 EPS for the quarter, topping the consensus estimate of $6.49 by $0.15. The firm had revenue of $1.20 billion for the quarter, compared to the consensus estimate of $1.17 billion. Jazz Pharmaceuticals had a positive return on equity of 6.87% and a negative net margin of 8.35%.The business’s revenue for the quarter was up 8.1% compared to the same quarter last year. During the same quarter last year, the company earned $6.51 earnings per share. Analysts forecast that Jazz Pharmaceuticals will post 16.96 EPS for the current year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.